Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Mohamed El Mouelhi"'
Autor:
Mohamed El Mouelhi
Publikováno v:
Egyptian Liver Journal. 8:1-5
Drug development process faces many challenges, including those encountered in clinical trials for liver diseases. Drug development is a lengthy and highly costly process. Only 10% of compounds entering first study in humans (phase 1) make it to the
Autor:
Mohamed El Mouelhi
Publikováno v:
Advanced Research in Gastroenterology & Hepatology. 13
Autor:
Mohamed El Mouelhi
Publikováno v:
Journal of Molecular Neuroscience. 58:374-378
Drug development process faces many challenges, including those encountered in clinical trials for neuromuscular diseases. Drug development is a lengthy and highly costly process. Out of 10 compounds entering first study in man (phase 1), only one co
Autor:
Christopher Grunseich, Ram Miller, Therese Swan, David J Glass, Mohamed El Mouelhi, Mara Fornaro, Olivier Petricoul, Igor Vostiar, Ronenn Roubenoff, Matthew N Meriggioli, Angela Kokkinis, Robert D Guber, Maher S Budron, John Vissing, Gianni Soraru, Tahseen Mozaffar, Albert Ludolph, John T Kissel, Kenneth H Fischbeck, Julia Dahlqvist, Nanna Witting, Ilaria Martinelli, Giorgia Querin, Namita A Goyal, Tiyonnoh M Cash, Brian Minton, Angela Rosenbohm, Ulrike Weiland, Patrick Weydt, Sharon Chelnick, Stanley Iyadurai, Wendy King
Publikováno v:
The Lancet. Neurology. 17(12)
Summary Background Spinal and bulbar muscular atrophy is an X-linked neuromuscular disease caused by CAG repeat expansion in the androgen receptor gene. Patients with this disease have low concentrations of insulin-like growth factor-1 (IGF-1), and s
Autor:
Victor L. Serebruany, Dominick J. Angiolillo, Hans Jürgen Pfannkuche, Kristine Rose, Martin L. Marro, Mohamed El Mouelhi
Publikováno v:
American Journal of Therapeutics. 17:543-552
A meta-analysis of 29 clinical studies on tegaserod revealed an imbalance of cardiovascular ischemic events in patients treated with drug versus placebo. Because increased platelet activity is known to attribute to cardiovascular events, we examined
Autor:
Elisabetta Cerbai, Alessadro Mugelli, Mohamed El Mouelhi, Hans-Jürgen Pfannkuche, Silvia Suffredini, Gabriele Giunti
Publikováno v:
Basic & Clinical Pharmacology & Toxicology.
Tegaserod (Teg), a 5-hydroxytryptamine type-4 (5-HT4) receptor partial agonist, represents a novel treatment for irritable bowel syndrome with constipation and chronic constipation. Cardiovascular safety data from pooled clinical studies showed a sig
Autor:
Victor L, Serebruany, Mohamed, El Mouelhi, Hans-Jürgen, Pfannkuche, Kristine, Rose, Martin, Marro, Dominick J, Angiolillo
Publikováno v:
American journal of therapeutics. 17(6)
A meta-analysis of 29 clinical studies on tegaserod revealed an imbalance of cardiovascular ischemic events in patients treated with drug versus placebo. Because increased platelet activity is known to attribute to cardiovascular events, we examined
Autor:
Rolf Gebhardt, Elke Röhrdanz, Iris Eisenmann-Tappe, Dieter Schrenk, Doris Mayer, Peter A. Münzel, Karl Walter Bock, Mohamed El Mouelhi
Publikováno v:
Biochemical Pharmacology. 41:1751-1757
P450-dependent mono-oxygenase and conjugating enzyme activities were studied in rat liver epithelial cells (RLEs) and compared to those in hepatocytes and bile duct cells. Various RLE cell lines were investigated since (a) they are suspected to be de
Publikováno v:
Journal of Liquid Chromatography. 13:505-524
On the basis of Nucleosil-100 a series of materials with varying structure and different coverage density of chemically bonded C18 phases (CBP) were prepared. The physico-chemical characteristics of these packings e.g. porosity and carbon content wer
Autor:
Jason D. Morrow, Raymond E. Galinsky, Charles Preuss, Mohamed El Mouelhi, Rose Kovelesky, Robert J. Noveck, Timi I. Edeki
Publikováno v:
Clinical pharmacology and therapeutics. 77(3)